A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.

Inclusion Criteria: * Has American Society of Anesthesiologists (ASA) Physical Status of I, II, or III. * Is scheduled to undergo a unilateral Total Shoulder Arthroplasty. Exclusion Criteria: * Is undergoing a revision surgery. * Has a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to bupivacaine (or other local anesthetics), NSAIDs, acetaminophen, oxycodone, morphine, or hydromorphone. * History of severe allergic reaction to aspirin or other NSAIDs, or known history of severe gastrointestinal adverse reactions associated with NSAID use. * Has taken meloxicam within 10 days prior to the scheduled surgery, or any NSAID within 24 hours prior to the scheduled surgery, with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection. * Opioid use for most days within the last 3 months prior to Screening in the opinion of the Investigator. * Has been administered immediate-release bupivacaine HCl within 5 days prior to the scheduled surgery, or a modified-release bupivacaine product within 14 days prior to the scheduled surgery. * Has initiated treatment with any of the following medications within 1 month prior to study drug administration: selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, gabapentin, pregabalin, duloxetine, or cyclooxygenase-2 inhibitors. * Has been administered systemic steroids within 5 half-lives or 10 days prior to the scheduled surge…